The role of activity in Synaptic degeneration in a protein misfolding disease, prion disease

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Caleo, Matteo ^a   Restani, Laura ^a   Vannini, Eleonora ^b   Siskova, Zuzana ^c,d   Al Malki, Hussain ^c   Morgan, Ruth ^c   O'Connor, Vincent ^c   Perry, V Hugh ^c  

^a CNR   (Italy)

^b SCUOLA NORMALE SUPERIORE   (Italy)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; HIPPOCAMPUS; MICROGLIA; MOUSE; NERVE DEGENERATION; NONHUMAN; PRESYNAPTIC NERVE; PRION DISEASE; PROTEIN FOLDING; PROTEIN MISFOLDING; SYNAPSE; SYNAPSE DEGENERATION; SYNAPTIC TRANSMISSION;

ANIMALS; BOTULINUM TOXINS, TYPE A; GENE SILENCING; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICROGLIA; MICROSCOPY, ELECTRON; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; PRION DISEASES; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; SYNAPSES;

MUS;

EID: 84864018982     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041182     Document Type: Article

References (52)

1. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
2. Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, et al. (2003) Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23: 5219-5226.
3. Rutten BP, Van der Kolk NM, Schafer S, van Zandvoort MA, Bayer TA, et al. (2005) Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol 167: 161-173.
4. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, et al. (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185: 232-240.
5. Frey D, Schneider C, Xu L, Borg J, Spooren W, et al. (2000) Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 20: 2534-2542.
6. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, et al. (2000) Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 26: 41-54.
7. Siskova Z, Page A, O'Connor V, Perry VH, (2009) Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol 175: 1610-1621.
8. Gray BC, Siskova Z, Perry VH, O'Connor V, (2009) Selective presynaptic degeneration in the synaptopathy associated with ME7-induced hippocampal pathology. Neurobiol Dis 35: 63-74.
9. Fernandez-Chacon R, Wolfel M, Nishimune H, Tabares L, Schmitz F, et al. (2004) The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron 42: 237-251.
10. Garcia-Junco-Clemente P, Cantero G, Gomez-Sanchez L, Linares-Clemente P, Martinez-Lopez JA, et al. (2010) Cysteine string protein-alpha prevents activity-dependent degeneration in GABAergic synapses. J Neurosci 30: 7377-7391.
11. Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, et al. (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480: 543-546.
12. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, et al. (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58: 42-51.
13. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, et al. (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48: 913-922.
14. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, et al. (2010) Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13: 190-196.
15. Pun S, Santos AF, Saxena S, Xu L, Caroni P, (2006) Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 9: 408-419.
16. Antonucci F, Di Garbo A, Novelli E, Manno I, Sartucci F, et al. (2008) Botulinum neurotoxin E (BoNT/E) reduces CA1 neuron loss and granule cell dispersion, with no effects on chronic seizures, in a mouse model of temporal lobe epilepsy. Exp Neurol 210: 388-401.
17. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M, (2008) Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28: 3689-3696.
18. Caleo M, Restani L, Gianfranceschi L, Costantin L, Rossi C, et al. (2007) Transient synaptic silencing of developing striate cortex has persistent effects on visual function and plasticity. J Neurosci 27: 4530-4540.
19. Bozzi Y, Costantin L, Antonucci F, Caleo M, (2006) Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res 9: 197-203.
20. Davletov B, Bajohrs M, Binz T, (2005) Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci 28: 446-452.
21. Johnson EA, (1999) Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol 53: 551-575.
22. Montecucco C, Molgo J, (2005) Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5: 274-279.
23. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, et al. (2008) Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70: 1699-1706.
24. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, et al. (2008) Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70: 1691-1698.
25. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH, (2005) Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 25: 9275-9284.
26. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z, (2011) Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186: 201-207.
27. Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, et al. (2011) Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 31: 15650-15659.
28. Hunt JM, Bommert K, Charlton MP, Kistner A, Habermann E, et al. (1994) A post-docking role for synaptobrevin in synaptic vesicle fusion. Neuron 12: 1269-1279.
29. Kao I, Drachman DB, Price DL, (1976) Botulinum toxin: mechanism of presynaptic blockade. Science 193: 1256-1258.
30. Ahmari SE, Buchanan J, Smith SJ, (2000) Assembly of presynaptic active zones from cytoplasmic transport packets. Nat Neurosci 3: 445-451.
31. Kreutzberg GW, (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312-318.
32. Ransohoff RM, Perry VH, (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27: 119-145.
33. Betmouni S, Perry VH, (1999) The acute inflammatory response in CNS following injection of prion brain homogenate or normal brain homogenate. Neuropathol Appl Neurobiol 25: 20-28.
34. Schiavo G, Matteoli M, Montecucco C, (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80: 717-766.
35. Capogna M, McKinney RA, O'Connor V, Gahwiler BH, Thompson SM, (1997) Ca2+ or Sr2+ partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin. J Neurosci 17: 7190-7202.
36. Siskova Z, Sanyal NK, Orban A, O'Connor V, Perry VH, (2010) Reactive hypertrophy of synaptic varicosities within the hippocampus of prion-infected mice. Biochem Soc Trans 38: 471-475.
37. Wree A, Mix E, Hawlitschka A, Antipova V, Witt M, et al. (2011) Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease. Neurobiol Dis 41: 291-298.
38. Sumner BE, (1977) Ultrastructural responses of the hypoglossal nucleus to the presence in the tongue of botulinum toxin, a quantitative study. Exp Brain Res 30: 313-321.
39. Graeber MB, (2010) Changing face of microglia. Science 330: 783-788.
40. Tremblay ME, Lowery RL, Majewska AK, (2010) Microglial interactions with synapses are modulated by visual experience. PLoS Biol 8: e1000527.
41. Barron RM, Campbell SL, King D, Bellon A, Chapman KE, et al. (2007) High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo. J Biol Chem 282: 35878-35886.
42. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, et al. (1997) Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275: 402-405.
43. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
44. Selkoe DJ, (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17: 1060-1065.
45. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, et al. (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25: 7709-7717.
46. Perry VH, (2010) Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol 120: 277-286.
47. Cunningham C, Deacon R, Wells H, Boche D, Waters S, et al. (2003) Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci 17: 2147-2155.
48. Parkyn CJ, Vermeulen EG, Mootoosamy RC, Sunyach C, Jacobsen C, et al. (2008) LRP1 controls biosynthetic and endocytic trafficking of neuronal prion protein. J Cell Sci 121: 773-783.
49. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, et al. (2011) Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun 2: 281.
50. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, et al. (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 30: 6367-6374.
51. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128-1132.
52. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, et al. (2010) Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med 12: 13-26.